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EMARKABLE IMPROVEMENT in the cure rate of children with acute lymphoblastic leukemia (ALL) has occurred over the past 30 years. In contrast, the results of treatment of adults with ALL remain poor despite adoption of strategies used successfully in children. Recent progress in classification of patients according to expression of specific patterns of cell-surface markers, in identification of genes responsible for the development of leukemia, and in understanding the mechanisms by which these genes cause leukemia may lead to more effective treatment. This review critically analyzes current results of treatment in adult ALL and summarizes recent advances in the biology of adult ALL and their application to the design of more effective treatment for this disease.
THE BIOLOGY OF ALL

Cell-Surface Proteins
The generation of highly specific monoclonal antibodies (MoAbs) against cell-surface proteins has advanced our understanding of both normal and malignant
hematopoiesis. An enormous number of MoAbs to cell-surface antigens are now commercially available. A series of International Workshops on Human Leukocyte Differentiation Antigens identified groups of MoAbs that recognize the same antigens, called cluster designations (CDs).' Fluorescence-activated cell sorting (FACS) can be used to determine reactivity of blast cells to a panel of these antibodies. Using different fluorescent tags, a cell can be stained simultaneously with several different antibodies. The reactivity of leukemic cells to a combination of antibodies establishes their pattern of antigenic expression, or "immunophenotype," which generally provides a more accurate assessment of their lineage and stage of maturation than do morphology and cytochemistry alone.
ALL is a heterogenous disease with distinct biologic and clinical features displayed by various subtypes. Lymphoblastic leukemias are generally initiated in B-or T-cell progenitors that arrest at various levels of maturation and proliferate. Immunophenotypic studies of normal lymphocyte development have made it possible to categorize leukemias of both B-and T-cell lineage based on their stage of maturation.
B-Cell Lineage ALL
Roughly 75% of cases of adult ALL are of B-cell lineage. More than 20 cells of B lineage. CD19, cytoplasmic CD22, CD24, CD10, CD20, surface CD22, cytoplasmic Ig, CD21, surface Ig, and CD23 are expressed sequentially during B-cell ~ntogeny.'.~ CD19, an antigen recognized by the antibodies B4 and Leul2, is expressed earliest and is present in more than 95% of ALLs. Early pre-B cells express membrane antigens shared by more mature B cells and have rearrangement of their Ig heavy chain genes, but lack surface or cytoplasmic Ig. Most are CDlO+ (the common ALL antigen, CALLA) and some express CD34, the stem-cell-associated antigen. The early pre-B cell phenotype has generally been associated with the most favorable prognosis in all age group^^-^ (Table   1) . It is the predominant immunophenotype in ~hildren'.~.~ but is less frequent in adult^.^.^." Pre-B cells commonly express CD10 and B-cell surface markers and have undergone Ig gene rearrangement, but do not express surface Ig. Their hallmark is expression of cytoplasmic Ig (p-chains) that has not been analyzed in most adult studies. Most of the data collected on adults with pre-B cell ALL is limited to adolescent patients5 Malignant cells with a mature B-cell phenotype express surface membrane Ig.
T-cell Lineage ALL
Approximately 25% of adult ALL cases are of T-cell lineage. Pre-T cell leukemias express cell-surface CD7 and cytoplasmic CD3 but not other T-cell markers such as surface CD3, CD4, or CD8. The survival of patients with the pre-T phenotype appears poorer than that of patients with a more mature T-cell phenotype. However, two recent large Abbreviations: S, surface; C, cytoplasmic; lg. immunoglobulin; -, negative; +,
Abnormalities associated with a poorer prognosis compared to leukemias of multicenter trials from Europe yielded conflicting results.
A German study showed a poorer prognosis for the pre-T phenotype whereas a more recent French study detected no difference in It is important to emphasize that prognosis by immunophenotype is often strongly influenced by the therapeutic regimen.
ALL With Myeloid-Associated Antigens
Previously, patients whose ALL cells expressed one myeloid marker were categorized as having "acute mixed lineage leukemia." l 3 Presently, however, these leukemias are described as "lymphoid leukemias" with myeloid-associated antigens.14 Myeloid lineage-associated antigens are detected in approximately 20% of adult ALL cases. Although some studies have reported a higher incidence, the diagnosis of ALL in these studies was based on light microscopy and cytochemical stains, and included patients whose leukemias lacked T-or B-cell-associated surface markers. Leukemias, previously described as ALL that lack T-and B-cell surface markers but express myeloid antigens, represent proliferation of early myeloblast^'^ and in 199 1 were classified as FrenchAmerican-British (FAB) group AML-MO." These blasts are undifferentiated by light microscopy including cytochemistries but myeloperoxidase is detected by electron microscopy. Detection of CD13 or CD33 supports this diagnosis. The MoAbs most commonly used for identification of myeloid antigen positive ALL are CD13, CD14, CD15, CD33, and CDW65. The expression of myeloid-associated antigens in adult ALL has been associated with a substantially reduced complete remission (CR) rate and poor long-term survival in someI7 but not all ~tudies.''.'~
Cytogenetic and Molecular Studies
Approximately half of adult ALL cases have clonal structural chromosomal abnormalities of which translocations have been studied in greatest detail. Translocations deregulate candidate oncogenes by a variety of mechanisms. Creation of fusion genes results in the formation of chimeric mRNA which, in most cases, are translated into chimeric proteins such as BCR-ABL. Other translocations result in aberrant expression of an otherwise normal gene product caused by introduction of a "heterologous" promoter or enhancer. This is the case for many of the translocations in T-cell ALL that result in deregulation of a variety of transcription factors.*" The pivotal role of specific translocations in initiating a cascade of cellular changes that eventually results in malignancy has been clearly shown in transgenic mouse models." However, the time required for the development of clinically evident leukemia in these models suggests a requirement for additional genetic changes. Many chromosomal translocations are associated with specific subtypes of ALL (Table 1) .
In view of the importance of specific cytogenetic abnormalities in defining the biology and prognosis of disease in patients with ALL, it is unfortunate that insufficient metaphase analysis is performed in adult ALL. The paucity of data limits conclusions as to the frequency and prognosis of specific abnormalities as well as therapeutic strategy in individual patients.
Chromosomal Translocations
Translocation (9; 22). Studies of the t(9; 22) illustrate the many ways molecular biology contributes to the diagnosis, treatment, and understanding of leukemia. C-abl, the cellular homologue of a retroviral oncogene, is translocated from its normal position on chromosome 9 to the breakpoint cluster region (BCR) on chromosome 22, resulting in the creation of a chimeric tyrosine kinase, BCR-ABL, with markedly increased activity compared with the normal activity of the c-ABL protein.'*-'' The increased tyrosine kinase activity results in increased cell proliferation and leukemogenesis through mechanisms that have not been clearly defined. Approximately 30% of adult ALL cases, predominantly of B lineage, contain a BCR-ABL fusion gene (as identified by DNA rearrangement), making it the most frequently identified translocation in this group.2s Cytogenetic analysis generally detects at least half of the patients with BCR-ABL.*X,2'
Most commonly BCR-ABL results from a reciprocal translocation between chromosomes 9 and 22 generating the classic Phl chromosome. In the remaining cases, a complex translocation involving a third chromosome masks the Ph' marker chromosome or the fusion gene is created by the insertion of ABL sequences into the BCR gene of a normalappearing chromosome 22. About half of adult patients express the p190 protein produced by fusion of BCR exon 1 to ab1 exon 2. The remaining patients express the p210 protein produced by fusion of either BCR exon 2 or exon 3 to ABL exon 2. The extent of BCR sequence at the amino terminus is the only difference between the p190 and p210 proteins. Most studies have found no substantial differences in clinical presentation or outcome between groups of patients with the p190 compared to the p210.'0"2 However, a study that treated chronic myelogenous leukemia (CML) patients with a-interferon found that the two types of p210 differed in their response rate as time to development of blast crisis.33 It is not yet known if this difference is relevant to Ph'-positive ALL.
Phl-positive ALL may vary with regard to the lineage commitment of the t(9;22) cell. Secker-Walker and Craig have shown that patients in whom lymphoid and myeloid cells were both Ph'-positive had a significantly longer eventfree survival compared with "lymphoid committed" cases in which only the lymphoid cells were Ph'-positive (median survival 35 months v less than 6 months).34
The BCR-ABL rearrangement is associated with a dismal prognosis in both pediatric and adult ALL populations. The proportion of ALL patients who are BCR-ABL-positive increases with increasing age.32 In adults, the CR rate is similar to that for ALL lacking the t(9;22) but the relapse rate is significantly highe?' and long-term leukemia-free survival is extremely rare. Recent studies from Cancer and Leukemia Group B (CALGB)Z8 and Southwest Oncology Group (SWOG)Z9 have failed to demonstrate that detection of BCR-ABL, only by molecular methods, carries as strong a prognostic effect as has been associated with detection of the Ph' by cytogenetics. However, those studies are based on relatively small numbers of patients and follow-up is short. In light of its probable prognostic importance, evidence for the BCR-ABL rearrangement should be sought at the molecular level in cases without an apparent Ph' chromosome on routine cytogenetic analysis. Patients with the BCR-ABL rearrangement should be considered for aggressive postinduction therapy, preferably as part of controlled clinical trials.
Translocations involving 11923. Chromosome segment l lq23 is involved in translocations with a variety of other chromosomes in ALL. The 5' portion of the MLL (mixed lineage leukemia, also called HRX, ALL-1) gene at 1 lq23 is fused to the 3' portion of the partner gene AF-4 (FEL), ENL (LTG19), or AF-9 located on chromosome 4q21, 1 9~1 3 , or 9p22, r e~p e c t i v e l y .~~~~~ These translocations may result in leukemogenesis through production of chimeric transcription factors that bind DNA and inappropriately deregulate subordinate genes. Treatment-related acute leukemias frequently have abnormalities of 1 lq23, most commonly involving the MLL gene. This is especially true for leukemias arising in patients whose previous therapy included epipodophyllotox-AML, ALL can also arise in this ~etting.~"'
The most common translocation involving 1 lq23, t(4; 11) (q21 ;q23) occurs in approximately 60% of ALL cases in infants younger than 1 year, in 2% of childhood ALL and in 3% to 6% of adults with ALL.47,48 In all age groups, this translocation is associated with hyperleukocytosis, CD10-early pre-B or pre-B phenotype (often with coexpression of myeloid-associated antigens) and a poor prognosis. Adults with this translocation have shorter event-free survival than ~hildren.4~ Chen et al," using molecular analysis, recently reported detection of the l lq23 rearrangement in 7 of 16 infants who did not have an llq23 cytogenetic abnormality. Insufficient metaphases for complete cytogenetic analysis were present in five of these patients. Molecular detection of 1 lq23 was also associated with a poor outcome.
Translocation (l; 19 T-cell ALL cases.67 TCR promotedenhancer elements are most likely responsible for the aberrant transcription of the gene located at or near the breakpoint on the non-TCR chromosome. Most of these proven or putative transcription factors including helix-loop-helix (Lyl-l, Tall , Tal-2) homeodomain (hox-ll), or LIM domain (Ttg-l/ Rhom-l, Ttg-Z/Rhom-2) genes. The Tal-l gene can be inactivated by an interstitial deletion. Tal-l deletion may be the most common genetic abnormality in T cell ALL, occurring in 25% of patients, including those without cytogenetic abnormalities of chromosome 1~3 2 .~' Many of the translocations involving TCR genes as well as the Tal-l deletions appear to be mediated by the same site-specific DNA recombinase responsible for normal Ig and TCR gene assembly.
Other genetic abnormalities. Other nonrandom structural abnormalities including partial or complete chromosomal loss or duplication suggest involvement of genes whose absence or over-activity is essential in the development or progression of neoplasia. In ALL, these include monosomy 7 (often associated with the Philadelphia chromosome), deletions of 9p, and duplications of lq and 2q4 ' The development of techniques to analyze larger regions of DNA, such as pulsed-field gel electrophoresis and yeast artificial chromosomes, coupled with the increasing numbers of human DNA probes, provide the means for identifying the responsible genes. It remains to be seen if the sequence of genetic events in the transformation of lymphocytes will be similar to that seen in solid tumors where, for example, the accumulation of genetic changes can be correlated with the pathologic progression from hyperplasia to neoplasia of the colon. The tumor suppressor gene p53 is frequently altered in solid tumors. Although p53 mutations have been detected in only 2% of a large group of lymphoid malignancies, mutations in p53 have been seen in up to 25% of the Burkitt's leukemia/lyrnph~mas.~~
Human T-cell Lymphotropic Virus-l (HTLV-l) Associated Leukemia
Adult T-cell leukemidlymphoma (ATL) caused by HTLV-1 should be suspected in cases of T-ALL associated with hypercalcemia and lytic bone lesions. The vast majority of ATL cases occur in patients from endemic areas (or whose families are from endemic areas), ie, southern Japan, the southern Pacific basin, the Caribbean basin, or sub-Saharan Africa. Other isolated areas with high prevalence include northern Iran, southeastern India, the Seychelle Islands, and Hawaii. HTLV-I -positive adult T-cell ALL is rare in the United States and Europe except in areas with large migrant populations where the incidence is similar to that in the endemic area of origin." Epidemiologic studies from Japan indicate that ATL is a rare complication of HTLV-1 infection, with less than 0.1% of carriers developing di~ease.~' Demonstration of monoclonal integration of HTLV-l proviral sequences by Southern blot hybridization or polymerase chain reaction (PCR) is the sine qua non of ATL. The molecular mechanisms by which HTLV-l infection results in leukemia in some individuals is unclear (see review by Rosenblatt et a17'). The most common recurrent chromosomal abnormalities include translocations of 14q32 or 14ql1, and partial or complete deletion of 6q (involving 6q21 in all but one case).73 These patients have a rapidly progressive clinical course and relatively short survival despite aggressive combination ~hemotherapy.~~ It remains to be seen if newer treatment strategies can improve therapeutic results. The recent demonstration that CD34' hematopoietic progenitors from patients with ATL did not contain HTLV-l DNA raises the possibility of isolation of such cells from bone marrow (BM) or peripheral blood (PB) for autologous transplantation after marrow ablative therapies.75
Minimal Residual Disease
At diagnosis, patients generally have a leukemia cell burden of lo'* cells. Although disease undetectable by conventional methods has been labeled "minimal residual disease' ' (MRD), the number of malignant cells may be as high as IO." Theoretically, all tumor cells must be eradicated to achieve cure. The ability to detect and quantitate malignant cells in patients in CR has permitted analysis of the effectiveness of various treatments and the biology of the disease during and after treatment. Current methods to detect small numbers of residual lymphoblasts after therapy and achievement of CR include flow cytometry and immunophenotyping, clonogenic assays for leukemia progenitor cells, and utilization of PCR for amplification of leukemia-specific sequences of RNA or DNA. One approach to improving treatment in ALL is to base treatment decisions on the detection and quantitation of leukemia cells after induction therapy and at specific times during subsequent treatment. For example, less than satisfactory progress during serial monitoring of a particular patient in remission might be used to determine the need for alternate treatment.
PCR methods based on identification of clonal rearrangements of the Ig heavy chain or TCRs offer an extremely sensitive technique by which one tumor cell can be detected among normal cells. Yamada et aI7'j identified complementarity-determining region 111 sequences with PCR to estimate the number of leukemic cells in the marrow of patients with B-lineage ALL before and after remission. Although induction therapy produces up to 3 or 4 log reductions in the leukemia cell burden, roughly lo8 or IOy malignant cells remain in most patients. Furthermore, marrow samples obtained throughout the first year after CR usually show minimal residual disease, supporting the need for longterm
Patients with detectable molecular residual disease at the completion of therapy eventually relapse. Thus, detection of residual disease after induction therapy, during postremission therapy, and at the completion of therapy is a powerful tool to monitor the effectiveness of treatment in a specific individual. The ability to quantitate response of malignant cells to specific treatment approaches offers the potential for a more scientific basis for development of treatment strategies. However, the necessity of sequencing each individual patient's antigen receptor gene rearrangement to create specific oligonucleotide probes for PCR may be a significant drawback to the use of this method of MRD detection outside of research settings.
Uckun et a17X developed a quantitative assay to detect MRD in ALL using a combination of flow cytometry and cell sorting with assays of leukemic progenitor cell colonies. The leukemic progenitor cell content of remission marrow varied from 0 to 1.25% of mononuclear cells. The count of leukemic progenitor cells before autologous transplantation showed a significant inverse correlation with the duration of remission after transplantation ( P < .001). In this study, there was no significant effect of purging the autograft to zero measurable leukemic progenitors on relapse. This detection system offers several advantages over molecular analyses. including the absence of a requirement for a clonal chromosomal abnormality or specific probe for an individual clone and the discrimination between blasts of differing c10-nogenicity potential. Unfortunately, the cumbersomeness of this approach limits its potential for widespread application. In Ph'-positive patients, reverse transcriptase (RT) PCR after therapy appear to be of value. Gehly et a179 found that all eight patients with Ph+ ALL in clinical CR after induction therapy, including three with no detectable Ph'-positive metaphases detectable, were positive by PCR. PCR positivity was an early indicator of relap~e.'~ Six of seven patients with Ph'-positive ALL who underwent BM transplantation (BMT) in cytogenetic CR were positive for BCR-ABL mRNA by PCR after transplantation. Any positive PCR result in the posttransplant period was associated with relapse." In contrast, the same investigators found prolonged PCR positivity in some patients with CML after BMT that was not associated with clinical relapse up to 2 years posttransplant.8' Newer techniques, such as competitive PCR, which provide a quantitative rather than qualitative assessment may prove to be more helpful in the assessment of individual patients at specific treatment intervals.'* Differences Between Pediatric and Adult ALL Compared to children, adults with ALL have lower CR rates and substantially poorer rates of long-term survival. The differing prognoses in adults and children have been attributed to differences in disease biology, including a higher incidence in adults of specific chromosome translocations associated with poor prognoses, especially the Ph' chromosome. There are also differences in treatment tolerance that distinguish these two age groups ( Table 2) .
Methotrexate Metabolism
There are differences in metabolism of chemotherapeutic agents related to age. Individuals vary in their processing of antimetabolites such as methotrexate (MTX) and 6-mercaptopurine. Polyglutamated forms of MTX are retained within the cell longer than the parent drug. MTX and MTX polyglutamates are similar in their ability to inhibit dihydrofolate reducatase. However, the polyglutamates are potent inhibitors of several enzymes in de novo purine synthesis that are not inhibited by MTX.83.&1 Increased formation of long-chain MTX polyglutamates in vitro correlates with better prognosis in pediatric B-lineage leukemia^.^' B-lineage blasts in adults with ALL accumulate significantly lower levels of MTX polyglutamates compared to children with this disease.86 This may contribute to shorter remission duration in adults because MTX is a commonly administered drug in postinduction therapy. In addition, it may be but one example of differences in drug metabolism between children and adults that might help explain differences in responses to similar drug regimens.
MDR-l Expression
Another potential factor in the poorer response to chemotherapy in adults may be related to expression of the multidrug resistance (MDR1)-associated membrane protein (p-170). MDRl functions as an adenosine triphosphate-dependent efflux pump for many compounds including a variety of chemotherapeutic agents." Expression of MDR-1 at diagnosis had no effect on the probability of entering CR for pediatric patients, but in adults, the CR rate was significantly lower in MDR-positive cases (56%) compared with MDRnegative cases (93%). MDR-positive patients were significantly more likely to relapse in both age groups (100% of adults and 73% of children).88 Adults, but not children, commonly express MDRl at the time of relapse, perhaps indicating an important role for MDRl in failure to achieve cure with first-line therapy in adults.89 Pre-T cell ALLs are more likely to express MDR-1 than ALLs with a more mature T phenotype." This may be a factor in the poorer survival of these very immature T-cell le~kemias."~~' Development of drugs that can be used clinically to overcome MDR1-mediated resistance would permit tailored therapy based on expression of MDR1.
Treatment Tolerance
Additional reasons for poorer outcome in older patients include greater hematologic toxicity leading to treatment delays and a higher incidence of life-threatening infections, and more nonhematologic toxicity, eg, hepatic and cardiotoxicity resulting in higher morbidity and mortal it^.^' Adults receiving less than specified treatment fare substantially worse than those receiving full Interestingly, better diseasefree survival has been reported among patients ages 15 to 20 who have been treated in pediatric departments than those of similar ages treated in adult department^.^^." It has been speculated that patients and physicians at pediatric centers may be more compliant with intensive, prolonged chemotherapeutic regimens.
Although the application of therapeutic strategies proven effective in children has improved results in adults with ALL, it is clear that older age is an unfavorable prognostic feature even when using similar t h e r a p i e~.~'~~.~ Based on the sharp peak in incidence of ALL in young children in the United States and Great Britain, but not Africa, and the uniformity of its B-cell lineage and rarity of unfavorable karyotype in the pediatric population, MaueP7 has speculated that many children have a different form of ALL than that usually seen in adults. If it is essentially correct that most children have a form of disease distinct from that seen in adults, substantial improvement in results in adults will likely require innovative therapeutic strategies, rather than attempts to apply strategies effective in most children to adults.
TREATMENT OF ADULT ALL
Results of Recent Clinical Trials
It is widely accepted that more than one third and perhaps as many as 40% of unselected adults with acute lymphoblastic leukemia (ALL) are cured by modem chemotherapeutic regirnen~.'~''~ These estimates are derived from well-publicized results of some studies'O.'w'os as well as retrospective analyses of cohorts of patients pooled from published large ~~s * l o , ' 9 . 1 w ' 2 3 These estimates are inaccurate for a number of reasons, primarily patient exclusion, inadequate followup, and emphasis on single institutional studies that are not validated in multi-institutional trials.
First, results of treatment in adult (but not childhood) ALL, are reported, by convention, as disease-free survival and consider only those patients who enter CR, excluding the 20% to 40% of individuals who fail to achieve CR. Because of this factor alone, the common practice of equating disease-free survival figures with the proportion of patients cured overstates "cures" by roughly one third.'" In addition, a substantial proportion of patients are excluded from analyses for various reasons. For example, because many trials were randomized studies designed to compare different forms of postinduction chemotherapy, the reported rates of disease-free survival exclude patients who relapsed or died after obtaining remission but before receiving postinduction therapy."o."2,"7*1'9 In some studies, only patients who survived free of disease for sufficient durations to receive postconsolidation therapy are included in analysis of disease-free ~urvival."~ Patients who withdrew or who were withdrawn from study by physicians (often because of treatment toxicity or coexisting medical problems) or who demonstrated poor compliance were usually excluded from analyses of disease-free ~u r v i v a 1 . '~~"~~' '~~'~~ Patients with adverse risk factors such as the Ph chromosome (Ph') were sometimes selected for allogeneic BMT and censored from analysis. Several studies excluded patients with adverse risk factors, including emergency treatment with chemotherapy for high white blood cell ( W C ) count at presentati~n,"~~"~ age >50,'05.'12 Ph','0*'043105 or B-cell phenotype.lo5 In several studies that did not exclude older patients, there was an obvious failure to register older individuals as demonstrated by very young patient populations (median age <30).'9""'"~''3~''9,'2'
Although many of these practices may have been appropriate for the specific goals of individual trials, they should preclude the application of estimates of disease-free survival generated in these trials to the general population of adults with ALL.
Second, disease-free survival rates are routinely cited at 2, 3, 4, or 5 years in studies where patients continued to relapse beyond these periods. Long-term follow-up consistently shows lower rates of sustained disease-free survival than initially reported.'12,122.124
Last, trials with favorable results are frequently cited even when subsequent trials fail to validate initial results. Variations in results are usually attributed to modifications in treatment but may be related to differing patient characteristics in different trials. For example, the favorable results of the L-lO/L-lOM protocol seen at Memorial Sloan Kettering Cancer Center" were not verified when studied in a multiinstitutional trial through the Southwest Oncology Group.Iw A substantially higher proportion of older patients and the inclusion of Ph'-positive patients contributed to the poorer results. It is worth noting that no American cooperative group trial has shown cure rates in excess of 20% with any chemotherapeutic protocol. Considering the previously noted selection and exclusion biases of these studies, it is reasonable to conclude that less than 20% of adults with ALL have been cured by modem chemotherapeutic regimens.
Components of Modern Chemotherapeutic Protocols
Conventional therapy of ALL previously consisted of four parts-induction, consolidation, maintenance, and CNS prophylaxis. However, many recent treatment protocols have not followed traditional definitions of these approaches. Induction therapy and postremission therapy are appropriate terms for the stages of treatment in recent trials.95
Induction Therapy
The traditional goal of induction therapy in ALL is to reduce the number of leukemic cells to below that detectable by conventional methods. The success of induction therapy, as measured by the ability to quickly achieve CR, is an important prognostic factor in patients with adult ALL.% Randomized and nonrandomized studies show that the addition of anthracyclines to vincristine and prednisone alone or in combination with L-asparaginase improve the CR rates in most adult studies from 50% to 6 0 % to greater than 70% and improve duration of remi~sion?~*'''~'~~ De ath during induction and resistant disease comprise similar proportions of the patients who do not achieve CR.
Attempts to further intensify induction treatment have not been shown to improve the survival of unselected groups of adults with ALL. The addition of cyclophosphamide'" or a single high dose of cytarabine" during induction did not improve the proportion of patients achieving CR nor the duration of CR, but increased hematologic toxicity. A randomized ECOG trial comparing standard induction with daunorubicin, vincristine, and prednisone to a more intensive induction regimen with an increased daunorubicin dose, cytarabine, and 6-thioguanine did not show clear benefit.'% An attempt to intensify induction by addition of intermediate doses of cytarabine and idarubicin to standard vincristine and prednisone led to unacceptably high treatment related In summary, induction with an anthracycline, vincristine, and prednisone appears to result in optimal effec-tiveness with minimal morbidity and mortality in most adults with ALL. Most attempts to intensify induction therapy have been limited by severe toxicity.
Postremission Therapy
If no systemic therapy is administered to patients once remission is achieved, relapse will occur quickly.'28 The fact that lo8 to lo9 residual tumor cells can generally be detected with molecular techniques in patients in CR after induction therapy, as detailed previously, helps to explain this. The goal of therapy, once remission is achieved, is to eradicate all malignant cells, ie, those that are undetected by conventional techniques. Studies from Memorial-Sloan Kettering Cancer Center in the 1970s, using 2 to 3 months of consolidation therapy with cytarabine, thioguanine, and methotrexate, led to long-term survival in roughly one third of patients who had achieved remission.112 However, large randomized studies by multicenter groups failed to demonstrate a benefit for consolidation identical to that of the L-l0 protocol from Sloan Kettering compared to 1 month of consolidation with L-asparaginase and cycloph~sphamide"~ or for postremission therapy with two courses of cytarabine and daunorubicin as administered to patients with In addition, this intensification was toxic, resulting in hospitalization and, occasionally, death caused by infection. A nonrandomized study by ECOG showed no significant benefit in diseasefree survival using high dose Ara-C for intensification. '26 Although the effectiveness of intensive postremission therapy has not been established in controlled studies, several sequential studies suggest that this approach leads to improved duration of CR.' "*"*"'
The German BFM (BerlinFrankfurt-Munster) multicenter trials using reinduction, ie, chemotherapy similar to induction given 3 months after CR, have resulted in the highest reported survival rates of any large series with similar criteria for patient selection.'" In more than 1,500 patients ages 15 to 65, induction regimens included prednisone, vincristine, daunorubicin, and L-asparaginase in the first 4 weeks of treatment followed by cyclophosphamide, cytarabine, 6-mercaptopurine, and intrathecal methotrexate. A similar "reinduction" is administered 3 months later. Thus, despite a lack of evidence from controlled trials, intensive postremission therapy, such as that used in the BFM protocols, appears to result in improved outcome.
"Maintenance" chemotherapy, ie, prolonged lower-dose treatment, prevents relapse in children with ALL, but has not been proven effective in adults. The main components of maintenance therapy are methotrexate and 6-mercaptopurine, often in combination with "pulses" of vincristine and prednisone. Higher cumulative chemotherapy dose^'^^.'^^ and dose adjustment to maintain WBC count less than 3.5 X lo9 L'31 are associated with lower relapse rates in children. The optimal duration of treatment is not known; however, after a modified BFM regimen children fare as well with 18 months as with 24 months of treatment,13' and that duration of treatment would appear adequate for adults.
Prevention of CNS Disease
Prophylactic treatment of the CNS is based on the premise that the CNS is a sanctuary for leukemic cells that are. protected from cytotoxic concentrations of drugs by the blood brain barrier. The demonstrated effectiveness of CNS therapy in children supports this view.'33 Although meningeal leukemia occurs less frequently in adults than in children, groups at high risk for CNS involvement, eg, those with an initial leukocyte count exceeding 50 X 109/L can be identified.'34 The Southeastern Cancer Study group randomized patients to receive CNS prophylaxis with cranial irradiation and intrathecal methotrexate or no prophylaxis. CNS relapse occurred in 11% and 32% of these groups, re~pective1y.l~~ Because of concerns regarding drug concentrations in the CSF with systemic therapy, craniospinal irradiation was initially used to prevent CNS disease. Doses of 2,400 cGy were effective in substantially reducing the incidence of CNS relapse and improving survival in ~h i l d r e n . '~~. '~~ Because of the toxicity of this radiation dose, it was subsequently lowered. Doses of 1,800 cGy with intrathecal methotrexate proved similarly effe~tive.'~~ The German multicenter study groups have used cranial irradiation after induction therapy along with intrathecal chemotherapy. In one study where radiation was delayed until reinduction therapy, a higher CNS relapse rate was seen.'" Intensive intraventricular therapy with methotrexate via Omaya reservoir, without irradiation, is also effective in prevention of CNS disease." Recent trials have reported effective CNS prophylaxis with highdose systemic methotrexate and/or ~y t a r a b i n e . '~~. '~ Treatment to prevent CNS relapse should be used in all adults with ALL. The combination of intrathecal and high-dose systemic chemotherapy is used by most programs. For the nearly 5% of individuals who present with CNS disease, intraventricular chemotherapy and cranial irradiation should be administered.
Prognostic Factors
The prognosis of patients with ALL, treated with modem chemotherapeutic regimens, is dependent on a number of variables. Independent poor-prognostic factors include older age, presenting leukocyte count greater than 50,000, CNS involvement, specific immunophenotype, eg, "B cell," cytogenetic abnormalities, eg, the Ph', t(4; 1 l), or t(8; 14), and longer time to achieve CR. The development of techniques to better identify different disease categories is an important potential strategy for improving treatment. Many investigators have attempted to group patients into standard and "high-risk" categories and treat the former group conservatively and the latter group aggressively. However, in view of the poor results previously cited it seems reasonable, at present, to treat the vast majority of adult ALL patients with intensive protocols and to tailor certain treatments to specific "high-risk" groups.
Treatment Tailored to Biologic Subsets of ALL
Recognition of the biologic heterogeneity of ALL and recent evidence that specific subtypes of ALL may respond better to specific therapies have raised the question of whether therapy should be tailored according to specific subtypes of ALL. Therapeutic approaches that have not been shown to improve overall results appear to be useful in specific patient populations.
T-cell Neoplasms
T-cell malignancies account for approximately 25% of adult ALL. Until recently, outcome was dismal, especially in those with mediastinal masses. Substantial improvement in outcome has been reported in recent trials that have included substantial doses of cyclophosphamide and cytosine arabinoside during initial treatment. In these trials, results in patients with T-cell malignancies are, at least comparable to, and frequently better than, those with other immunophemass adversely affects prognosis. These clinical data are supported by studies of human T lymphoblasts that are sensitive to cytosine arabinoside in vitro apparently because of their unique ability to accumulate high levels of cytosine arabinosine triphosphateiu and by murine studies demonstrating synergistic activity of cytosine arabinoside and cyclophosphamide against the AKR T-cell malignan~y.'~~ In a retrospective analysis of German multicenter studies, prognosis in patients with mediastinal tumors was improved by administration of local irradiation after initial chemothera~y . '~~ These treatment data on T-cell ALL have not been subjected to randomized study; however, the available data support the contention that all patients with T-cell ALL should be treated with regimens that include early administration of cyclophosphamide and cytarabine. 
Ph'-Positive ALL
Patients who are Ph'-positive have the worst prognosis of adults with ALL with few cures despite a substantial rate of achieving CR. Thus, traditional postinduction treatment is inadequate for this group. A recent report demonstrates prolonged disease-free survival in 4 of 1 1 pediatric adolescent patients who received an aggressive seven-drug induction regimen, followed by rotational combination chemotherapy15'; however, the best results in Ph'-positive ALL have been reported with myeloablative therapy followed by allogeneic BMT. Potential novel therapeutic approaches directed at the BCR-ABL fusion gene are discussed below (see Novel Treatment Strategies).
Aiiogeneic BMT
The timing of allogeneic BMT in the treatment of adult ALL is controversial. Transplantation is clearly the most effective way of eliminating leukemia in most patients. The effectiveness of allogeneic marrow transplantation results from both the high-dose chemotherapy t radiation therapy and the antileukemic activity of the donor cells.I5* The effectiveness of allogeneic transplantation is balanced by substantial early mortality caused by regimen-related toxicity and graft-versus-host disease (GVHD), long-term toxicities of the preparative regimen, and compromised quality of life in some individuals because of GVHD. Although these potential problems merit consideration, the most important factor in deciding whether to proceed with allogeneic BMT at a given time is generally whether it offers the best chance for long-term leukemia-free survival.
Because other forms of therapy are ineffective in producing sustained leukemia-free survival once relapse has occurred, allogeneic BMT is appropriate after relapse in patients less than 55 years of age with a histocompatible sibling donor. Because the majority of individuals can be induced into a second remission, transplantation is generally performed at that time. It is unclear whether results in second remission are better than those in early relapse. In some groups of patients, such as those in early relapse who are unlikely to achieve a second CR, transplantation in early first relapse might prove advantageous. An example of such a group might be those patients whose cells express MDRassociated P-glycoprotein, because only 15% will obtain a second CR.89 Twenty percent to 30% of adults undergoing allogeneic BMT from HLA-identical sibling donors in second CR are long-term leukemia-free survivor^.'^"'^^ Although transplantation can be performed late in the course of disease, transplantation should not be delayed beyond second remission. In patients who have relapsed, long-term results of allogeneic transplantation using matched unrelated donors appear ~i m i l a r '~~. '~~ to those achieved with sibling donors with an increased incidence of transplant-related mortality offset by a lower relapse rate.
Insufficient data exist to determine whether transplantation of adult ALL at the time of first remission is advantageous. A substantial majority of individuals who achieve CR will eventually relapse. The use of the most effective treatment, ie, allogeneic transplantation in patients with suitable sibling donors, is a logical approach; however, this approach has not been proven to be superior. Horowitz et all5' compared the effectiveness of intensive postremission chemotherapy in two cooperative group trials in West Germany to allogeneic transplant recipients in 98 hospitals who reported results to the International Bone Marrow Transplant Registry (IBMTR). Overall 5-year leukemia-free survival probability was 44% (95%, confidence interval [CI] 37% to 52%) for those who underwent transplantation and 38% (95%, C1 33% to 43%) with chemotherapy. The results of this study have been widely held to show that allogeneic transplantation offers no advantage over chemotherapy for adults with ALL in first remission. However, this study was not adequate to reach that conclusion. This retrospective study compared a homogeneously treated chemotherapy group with substantially better results than have been generally been reported to a transplantation group which was heterogeneously treated at 98 centers with a wide variety of preparative regimens and supportive measures. The group undergoing BMT experienced an unusually high rate of transplant-related mortality of 39%. Most single and multiin-stitutional studies report a transplant-related mortality of less than 30% for individuals with acute leukemia in first CR and better long-term results than were reported in this disease-free survival of 61% for 57 "high-risk" individuals with ALL who underwent allogeneic transplantation in first r e m i s s i~n . '~~ In a separate report on patients with ALL, the IBMTR observed that between 1980 and 1981 and 1988 and 1989 the probability of treatment-related mortality decreased from 39% 2 19% to 27% t 8% ( P < .OOOl), relapse rate declined from 26% t 20% to 19% 2 7% (P < .OOO3), and leukemia-free survival improved from 42% -t 20% to 57% 2 8% ( P < .0001).'6' A recent report of syngeneic transplantation from the IBMTR included a "control" group of 240 patients with ALL who underwent allogeneic BMT from HLA-identical siblings in first This group had a 3-year probability of treatment-related mortality of 21% (95% CI, 16% to 26%) and a 3-year probability of leukemiafree survival of 58% (C1 52% to 64%). Their median age was 22; the median age in the study of Horowitz et a1 was not provided; however, 70% of patients were less than 30. Thus, the high mortality rate reported in the allogeneic transplant group by the IBMTR study comparing transplantation to chemotherapy has not been validated by other groups nor by additional data from the IBMTR. The French Group on Therapy for Adult ALL performed a prospective study in which patients with ALL in first CR received allogeneic transplants if they had histocompatible sibling donors or were randomized to autologous transplant versus chemotherapy if they did not have a suitable donor.'63 The group that underwent allogeneic BMT had a 3-year disease-free survival of 47% ? 5%, whereas for the chemotherapy group it was 32% -t 5%. Furthermore, relapses after 36 months occurred in the chemotherapy arm. However, when considering intent to treat the disease-free survival for the transplant arm was 44% ? 5%. Additionally, patients older than 40 years were not eligible for allogeneic transplantation whereas the other groups included older patients. Because of the absence of randomization in the allotransplant arm, the investigators did not attempt to make statistical comparisons with the chemotherapy arm. Another factor complicating analysis of these data is that transplantation can be deferred in patients who are treated with chemotherapy and used to cure a proportion of those who relapse. Precisely how many individuals this strategy would benefit is not clear, however, because large proportions of patients who are eligible for allogeneic transplantation do not undergo this procedure.Ia In patients with ALL who relapse and for whom induction of a second remission is planned, substantial proportions of patients will die during treatment, fail to obtain a second CR, or will obtain CR but relapse before transplantation. Thus, although this strategy clearly might benefit some patients, the proportion is unclear. In summary, transplantation has not been proven more effective than chemotherapy in adults with ALL in first CR; however, this issue has not been adequately studied.
Transplantation in first remission is clearly the best option in certain subgroups. Forman et all6' demonstrated the effectiveness of allogeneic transplantation in individuals with Phlstudy.~52-154.158-160 The City of Hope and Stanford reported a positive ALL. The IBMTR subsequently reported leukemiafree survival of 38% in 33 Ph-positive ALL patients who underwent allogeneic transplantation in first CR.'" Individuals with t(4; 11) have a similarly dismal prognosis with chemotherapy alone but can be cured by allogeneic transplantationIti7 and, therefore, should undergo transplantation in first remission if an HLA-identical sibling donor is available. Patients with these translocations who have no sibling donors should be considered for transplants from matched unrelated donors early in the course of their disease. Other adverse risk factors such as older age, high WBC count, and slow response to induction therapy are not clear indications for transplantation because these appear to adversely affect transplant outcome as Patients who do not achieve a CR within 6 weeks have an exceedingly poor long-term prognosis. Because cure is unlikely with second-line therapy, allogeneic transplantation early in the course of disease in patients failing induction therapy is appropriate if HLA-compatible donors are available. Roughly 20% of patients with primary induction failure are reported to achieve sustained leukemia-free survival with allogeneic tran~plantation.'~~.'~~ Because outcome is better in patients with higher performance scores and for those who received fewer cycles of induction chemotherapy, early identification of patients unlikely to achieve remission is important.
A variety of preparative regimens have been used before allogeneic transplantation in ALL, generally with similar results. Total body irradiation (TBI) remains a crucial component of most effective regimens. Identification of patients at high risk for relapse with conventional TBI-containing regimens could lead to improved results. Uckun et al have demonstrated an association between immunophenotype and radiation sensitivity of leukemic blasts. Expression of CD3 surface antigens in T-lineage ALL'70 and lack of CD24 antigen in Blineage ALL'71 are associated with radiation resistance. Careful analyses of the effects of these immunophenotypes on outcome with TBI-based protocols would be of great interest. The use of radiation-free preparative regimenslm might prove useful in patients with radiation resistant blasts. Similarly the use of radiation-free regimens might not be wise in patients who demonstrate MDR-1 mediated resistance.
Identical-Twin Transplants
A recent report from the IBMTR described 24 patients with ALL in first CR who underwent transplantation from identical-twin donors.162 Unlike patients with AML or CML, these patients had a relapse risk (36%, 95% C1 17% to 55%) that was not significantly different from a group of patients undergoing HLA-identical sibling transplants. Three-year leukemia-free survival probability after their transplant was 57% (CI; 37% to 77%), consistent with evolving data that intensive postremission treatment is effective in many patients with ALL. Although small numbers of patients severely limit the power of analysis, these data suggest that autologous transplantation might be effective in ALL if leukemic cells in the graft could be effectively purged.
Autologous Transplantation
Although it has been thought that failure to eradicate systemic disease in the patient is the main limitation of auto-transplantation in ALL, the presence of malignant cells in the cryopreserved BM, even when procured in remission, must be addressed. Brenner et all7' have recently shown that genetically marked leukemic cells procured from patients in remission from acute leukemia can contribute to relapse after autologous BMT. Methods for purging malignant cells from procured marrow are of potential use. A variety of techniques including enrichment of normal hematopoietic progenitor cells, long-term BM culture techniques, and chemical as well as immunologic techniques have been used. Attempts to use antibodies to tumor cells have been plagued by the limited expression of specific antigens by some malignant cells, In addition, therapeutic purging techniques, particularly those using chemotherapeutic drugs can substantially slow engraftment and lead to prolonged and expensive hospital stays. Despite in vitro demonstration of substantial leukemic cell kill, clinical studies have failed to demonstrate a benefit for Unfortunately, clinical trials designed to address the benefit of purging autologous marrow in ALL have not been performed in a prospective, randomized manner. Such trials would require large numbers of patients as well as quantitative assessment of the effectiveness of purging techniques.
Some uncontrolled trials using autotransplantation in first or second remission have produced results superior to those generally seen with ~hernotherapy,'~' but no clear benefit for autologous transplantation has been seen in controlled trials. In the prospective multicenter randomized study by the French Group on Therapy for Adult ALL,'63 96 patients were randomly assigned to chemotherapy and 95 to autologous BMT. No significant differences in the incidence of treatment related-death, relapse, CR duration, or survival were detectable. Disease-free survival at 3 years was 39% 2 5% for the autologous BMT versus 32% ? 5% for the chemotherapy arm.
Although much of the data is inconclusive, most studies have achieved better results with allogeneic transplantation than with a~totransplantation.'~~.'~~ In a recently published French study, Vey et compared the results of 34 autologous and 29 allogeneic transplantation in adults with ALL and at least one poor prognostic factor who underwent transplantation in first CR. Most autologous marrows were immunologically or chemically purged. Although transplant-related mortality was 29% in the allogeneic group compared with 13% in the autologous group, the probability of relapse at 6 years was 10% and 65%, respectively. This study, which is important because of its long-term follow-up, demonstrated a disease-free survival of 62% at 6 years in the patients undergoing allogeneic transplant and 27% for those undergoing autologous transplant. A retrospective analysis from Seattle demonstrated better (though not statistically significant) leukemia-free survival in a cohort of patients with acute leukemia after unrelated transplantation compared with a disease, disease stage, and age-matched cohort of autologous recipients.'78
The effectiveness of allogeneic BMT and its antileukemic superiority to autologous transplantation results from the immune-mediated antileukemic effect of allogeneic BMT. This effect has been shown in animal models.'79 It is supported by numerous studies in which GVHD was associated with low relapse rates as well as improved long-term survival in some studies.160,18&182
At present, the role of autologous and allogeneic transplantation in patients with ALL in first remission has not been well defined. This is largely related to the substantial limitations of most published studies, including inadequate numbers of patients to achieve statistically significant differences in outcome unless huge differences are encountered, nonuniform selection criteria for different therapies and variations in the time from CR to BMT with different therapies.
An active international study between the Eastern Cooperative Oncology Group of the United States and the Medical Research Council of the United Kingdom'83 is designed to address these issues. In this prospective, randomized study all patients receive identical induction and intensification therapies. Those patients who attain CR and have a histocompatible sibling will undergo allogeneic BMT. Patients lacking compatible sibling donors will be randomized to autologous BMT or conventional maintenance therapy. It is crucial that eligible patients be entered into multicenter trials which will attempt to definitively answer crucial issues in management.
Novel Treatment Strategies
Cytokines
As previousiy stated, hematologic toxicity is an important limitation in the treatment of adults with ALL. Studies from the German Cooperative Group have demonstrated treatment delays in more than two thirds of A randomized trial from this group showed that patients undergoing induction therapy who received G-CSF 5 pgkg subcutaneously had a significantly shorter duration of neutropenia and fewer prolonged treatment delays compared with the group receiving no growth factor.'84 These results support those seen in prior nonrandomized studies using G-or GM-CSF.'85,'86 A similar randomized study by the Cancer and Leukemia Group B has demonstrated a significantly reduced time to neutrophil and platelet recovery with G-CSF.187 Whether the use of growth factors might improve outcome with chemotherapy by decreasing the incidence of infectious deaths and avoidance of treatment delays requires long-term follow-up of large randomized studies.
The proliferation of B-cell precursor ALL cells can be stimulated by lymphokines that regulate normal B-cell g r~w t h . '~* * '~~ Once the relevant genes are cloned and these factors are produced and clinically available, they could provide a method to recruit cells into cycle and enhance leukemic cell sensitivity to cell-cycle-specific chemotherapy.
MoAbs
Unconjugated MoAbs to lymphoid cell antigens have had disappointingly little effect clini~ally,'~~ apparently because of their limited capacity to kill malignant cells. Conjugates of MoAbs with drugs, radionucleoides, and toxins have been developed in an effort to enhance cytoto~icity.'~' Initial clinical trials using a variety of immunotoxins conjugated to MoAbs targeted against lymphoid antigens have shown that these agents can be given safely and can result in responses and occasional CRS.'~'"~ Attempts are currently being made to assess the effectiveness of these agents in patients with low tumor burden and limited prior therapy.
Approaches to Ph'-Positive ALL
Because of its frequency and its uniformly dismal prognosis, Ph'-positive ALL has received considerable attention from basic and clinical researchers. Therapy targeting the BCR-ABL fusion gene product is an attractive prospect for both CML and Ph'-positive ALL.
Approaches being explored include the specific cleavage of the fusion mRNA by engineered ribo~ymes'~~"~' and inhibition of mRNA translation by antisense ~lig~nucle~tide~.'~~~'~' Intriguingly, the earliest progenitor cell containing the t(9;22) may not express BCR-ABL fusion mRNA, raising theoretical problems for such strategies.'o'
Other potential therapies for Ph'-positive ALL include herbimycin A and interleukin-4 (L-4). Herbimycin A, a benzoquinonoid ansamycin antibiotic that specifically inhibits cytoplasmic tyrosine kinases, can produce growth arrest or differentiation of Ph'-positive leukemia^.^^-'^^ It also inhibited in vivo growth of V-ABL-expressing leukemic cells in nude mice, prolonging survival without apparent systemic toxicity.'" L -4 appears to inhibit growth of Ph'-positive ALL cell lines and primary leukemias while having no effect on Ph'-negative A L L S .~* '~~ The basis for this apparent specificity is not known. Phase I studies of L -4 in other lymphoid malignancies showed little toxicity, especially when compared with higher dose clinical trials of IL-4 in solid tumors.' OS a-Interferon, which has proven effective in reduction of Ph'-positive marrow cells in CML, has been used in ALL patients with BCR-ABL in postremission therapy;'" however, results are not mature.
An increasing awareness of the role of the immune system in the development of neoplastic diseases is stimulating research into how the immune function in patients can be manipulated for therapeutic effect. Translocations resulting in chimeric proteins, such as BCR-ABL, have a unique sequence at their point of fusion that would not normally be made. Therefore, a specific immune response should be mounted to "foreign" peptides derived from the fusion juncpeutic effect in ALL remains to be seen.
BCR-ABL provides a useful example of potential treatment strategies directed at specific gene products which influence the growth, differentiation, and death of leukemic cells. Approaches, eg, interference with gene expression by antisense oligonucleotides or with pharmacologic inhibition of biochemical pathways, affected by the products of these genes are being intensely pursued for a number of genetic abnormalities associated with ALL. tion.211.212 Whether this response can be exploited for thera-
SUMMARY
Despite reports to the contrary, only a small minority of adults with ALL are currently cured. Results have improved modestly with more intensive postremission chemotherapy and with tailoring of protocols in individuals with specific subsets of ALL. The use of growth factors may further improve treatment results. The performance of allogeneic BMT in first remission is clearly effective in some individuals, eg, those with Ph'-positive ALL, but it is unclear whether it is advantageous in most individuals. There are little data supporting the effectiveness of autotransplantation, as currently performed in ALL, despite its theoretical potential. Advances in understanding the biology of ALL have led to new approaches currently under basic and clinical investigation. These include serial studies of minimal residual disease by a variety of techniques to tailor treatment, the development of conjugated MoAbs to lymphoid cell antigens and immunologic and biochemical approaches to chimeric RNA and peptides generated by abnormal fusion genes. It seems likely that substantial improvement in the treatment of adult ALL awaits better characterization of the biology of this disease. However, some improvement will occur through empirical clinical research. It is critical that physicians recognize the poor results with current therapeutic approaches and enter patients into large well-designed clinical trials.
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